Breaking News, Collaborations & Alliances

Pfizer Opts in for Rights to RSV Candidate in China

Partner LianBio will receive $20 million upfront and is eligible to receive up to $135 million in potential development and commercial milestones.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer Inc. and LianBio, a biotechnology company in China, announced that Pfizer opted in to the right to develop and commercialize sisunatovir, a respiratory syncytial virus (RSV) therapeutic candidate, in Mainland China, Hong Kong, Macau, and Singapore under the companies’ existing strategic collaboration.   Sisunatovir is an investigational, orally administered fusion inhibitor designed to block RSV replication by inhibiting F-mediated fusion with the host cell. Sisunatovir is being evaluat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters